← All trials
NCT05759572
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2023
- Primary completion
- Nov 1, 2025
- Completion date
- Jun 1, 2027
- First posted
- Mar 8, 2023
- Last posted
- May 9, 2023
- Enrollment
- 145
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Nanjing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Fudan UniversityReponsible party - principal investigator
- Fujian Medical UniversityCollaborator
- Peking UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- Nantong UniversityCollaborator
- China Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.